6:05 PM
 | 
Apr 23, 2013
 |  BC Extra  |  Clinical News

Bristol-Myers reports more data for all-oral HCV regimen

Bristol-Myers Squibb Co. (NYSE:BMY) reported data on Tuesday from a Phase IIa trial evaluating an oral regimen of twice-daily asunaprevir, once-daily daclatasvir and twice-daily BMS-791325 to treat HCV genotype 1 infection in treatment-naïve, non-cirrhotic patients. In the first part of the trial,...

Read the full 199 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >